Replies to post #199794 on Biotech Values

[mr_o]

I disagree on that point. One of the discussed advantages of warfarin is the fact there is a reversal agent.

[DewDiligence]

PTLA -20%/PM on CRL for AndexXa (an antidote for oral FXa inhibitors f/k/a Andexanet alfa):

http://finance.yahoo.com/news/portola-pharmaceuticals-receives-complete-response-025707586.html

In the CRL for AndexXa, the FDA requested that Portola provide additional information primarily related to manufacturing. The agency also asked for additional data to support inclusion of edoxaban and enoxaparin in the label, and indicated it needs to finalize its review of the clinical amendments to Portola’s post-marketing commitments that recently were submitted.

Inasmuch as PTLA was down sharply yesterday, news of this CRL evidently leaked.

I'm skeptical of the market opportunity for this drug (#msg-120615780).